Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model.

The emergence of SARS-CoV-2 variants, especially Beta and Delta, has raised concerns about the reduced protection from previous infection or vaccination based on the original Wuhan-Hu-1 (D614) virus. To identify promising regimens for inducing neutralizing titers towards new variants, we evaluated monovalent and bivalent mRNA vaccines either as primary vaccination or as a booster in nonhuman primates (NHPs). Two mRNA vaccines, D614-based MRT5500 and Beta-based MRT5500ß, tested in sequential regimens or as a bivalent combination in naïve NHPs produced modest neutralizing titers to heterologous variants. However, when mRNA vaccines were administered as a booster to pre-immune NHPs, we observed a robust increase in neutralizing titers with expanded breadth towards all tested variants, and notably SARS-CoV-1. The breadth of the neutralizing response was independent of vaccine sequence or modality, as we further showed either MRT5500 or recombinant subunit Spike protein (with adjuvant) can serve as boosters to induce broadly neutralizing antibodies in the NHPs primed with MRT5500. The data support the notion that a third vaccination is key to boosting existing titers and improving the breadth of antibodies to address variants of concern, including those with an E484K mutation in the Receptor Binding Domain (RBD) (Beta, Gamma).

Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models.

Emergency use authorization of COVID vaccines has brought hope to mitigate pandemic of coronavirus disease 2019 (COVID-19). However, there remains a need for additional effective vaccines to meet the global demand and address the potential new viral variants. mRNA technologies offer an expeditious path alternative to traditional vaccine approaches. Here we describe the efforts to utilize an mRNA platform for rational design and evaluations of mRNA vaccine candidates based on the spike (S) glycoprotein of SARS-CoV-2. Several mRNA constructs of S-protein, including wild type, a pre-fusion stabilized mutant (2P), a furin cleavage-site mutant (GSAS) and a double mutant form (2P/GSAS), as well as others, were tested in animal models for their capacity to elicit neutralizing antibodies (nAbs). The lead 2P/GSAS candidate was further assessed in dose-ranging studies in mice and Cynomolgus macaques, and for efficacy in a Syrian golden hamster model. The selected 2P/GSAS vaccine formulation, designated MRT5500, elicited potent nAbs as measured in neutralization assays in all three preclinical models and more importantly, protected against SARS-CoV-2-induced weight loss and lung pathology in hamsters. In addition, MRT5500 elicited TH1-biased responses in both mouse and non-human primate (NHP), thus alleviating a hypothetical concern of potential vaccine-associated enhanced respiratory diseases known associated with TH2-biased responses. These data position MRT5500 as a viable vaccine candidate for entering clinical development.

Nanotechnology's Impact on Medicinal Chemistry.

Nanotechnology has intrigued a large number of researchers the world over owing to its unique properties as compared to bulk materials, and the novelty of applications made possible across many fields of science. Researchers, taking advantage of the unique properties of particles in nano (1-100 nm) form, have been developing nanoformulations of various medicinal compounds to enhance drug solubility, dissolution, and bioavailability. There are various methods by which drug compounds are conjugated to nanoparticles, and some bioactive compounds are attached by intermediary agents which are themselves usually part of the formation reaction of nanoparticles. Nanoformulations have been developed involving a range of medicinal compounds of biological and syntheticorigin intended to enhance the compound's pharmacokinetic and pharmacological profiles, or to capitalize on unique properties of nanoparticles for therapeutic or diagnostic purposes. A number of nanodrugs exist on the market today, and many more are in the clinical or pre-clinical pipeline. There are a number of challenges commonly encountered when designing nanodrug formulations as well as challenges to the long term viability of nanodrug formulation strategies, especially in regards to environmental and safety concerns. Some researchers have harnessed the structural and functional relationship of various medicinal compounds to enhance the design of nanoformulations. Other researchers have used structure-activity relationships as a means of enhancing safety and efficacy testing through in silico modeling. This article will touch on each of the above issues within the context of the impact each facet of nanotechnology has on medicinal chemistry.

Gold nanoparticles: various methods of synthesis and antibacterial applications.

Colloidal gold is very attractive for several applications in biotechnology because of its unique physical and chemical properties. Many different synthesis methods have been developed to generate gold nanoparticles (AuNPs). Here, we will introduce these methods and discuss the differences between fabrication techniques. We will also discuss ecofriendly synthesis methods being developed to efficiently generate AuNPs without the use of toxic substrates. Finally, we will discuss the medical applications for AuNPs by highlighting the potential use of intact or functionalized AuNPs in combating bacterial infections.

Biological applications of gold nanoparticles.

This article reviews some of the recent biological applications of gold nanoparticles (GNPs) which have been discovered lately by individual studies all around the world. GNPs have emerged as a promising candidates for various biological applications due to their unique physical properties (size and shape dependent), excellent biocompatibility, facile synthesis, ease of bioconjugation, etc. This review starts with a brief introduction about nanotechnology followed by an insight into the history, emergence, and enhanced properties of various gold nanostructures, which form the basis for their numerous biomedical applications. In addition, a brief overview on some of the commonly used fabrication techniques for synthesizing GNPs is also discussed. Finally, a miscellany of the latest biological applications of GNPs, such as cancer diagnostics and therapy, biological probes, drug delivery, gene delivery, vaccine preparation, brain implants, artificial skin, sterilization system, and improving electrical signaling in the heart, published in different articles in reputed journals are highlighted.

Antibacterial gold nanoparticles-biomass assisted synthesis and characterization.

Xylose is a natural monosaccharide found in biomass such as straw, pecan shells, cottonseed hulls, and corncobs. Using this monosaccharide, we report the facile, green synthesis and characterization of stable xylose encapsulated gold nanoparticles (Xyl-GNPs) with potent antibacterial activity. Xyl-GNPs were synthesized using the reduction property of xylose in an aqueous solution containing choloraurate anions carried out at room temperature and atmospheric pressure. These nanoparticles were stable and near spherical in shape with an average diameter of 15 +/- 5 nm. Microbiological assay results showed the concentration dependent antibacterial activity of these particles against both Gram-negative (Escherichia coli) and Gram-positive (Staphylococcus epidermidis) bacteria. Thus the facile, environmentally friendly Xyl-GNPs have many potential applications in chemical and biomedical industries, particularly in the development of antibacterial agents in the field of biomedicine.